Helus Pharma advances oral deuterated psilocin HLP003 for MDD, detailing new efficacy and safety analyses plus ongoing phase 3 PARADIGM trial updates.
|Articles|May 19, 2010
Factitious Disorders
Advertisement
Included in this category is the possible reclassification of factitious disorder to another diagnostic category.
Related Content
Advertisement
Related to this article
Caplyta phase 3 data show rapid, significant mania symptom relief in bipolar I by day 3, sustained to week 3, with tolerable adverse effects.
Atypical psychedelics such as ketamine, MDMA, and ibogaine show fast-acting promise for depression, PTSD, and addiction beyond 5-HT2A.
Spot SVT or POTS masquerading as panic attacks—key heart-rate clues, home maneuvers, and why anxiety can persist even after arrhythmia treatment.
Phase 3b data show centanafadine reduces adult ADHD and comorbid anxiety.
Medicare claims show pimavanserin in Parkinson psychosis nursing homes links to fewer falls and recurrent falls than quetiapine or other antipsychotics.
Learn how to prevent and spot tardive dyskinesia from antipsychotics, track key risk factors, and treat symptoms with VMAT2 inhibitors.
New real-world studies show Vraylar boosts depression relief, functioning, and quality of life in MDD and bipolar I patients beyond clinical trials.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Centanafadine For Comorbid ADHD and Anxiety: Talking New Data With John Kraus, MD, PhD
2
Positive Topline Phase 3 Study Results: Lumateperone for Manic Episodes in Bipolar I Disorder
3
The Top 7 Atypical Psychedelics: A Brief Clinical Guide
4
Brenipatide for Alcohol Use Disorder: Emerging Findings
5